Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Immunology stories

Oct 30, 2026

Hiroshima University finds hyperactive YAP/TAZ proteins help cancer cells evade immune system

Researchers at Hiroshima University and international collaborators discovered that hyperactive YAP and TAZ proteins, which promote cancer, are associated with genomic instability that enables tumor cells to evade immune system detection and destruction.

Oct 30, 2026·2 sources
00

Researchers trace uneven spread of herpes simplex virus 1 in skin organoids

Researchers at the Max Delbrück Center and University Medical Center Hamburg-Eppendorf have used skin organoids to trace how herpes simplex virus 1 infection progresses unevenly among neighboring skin cells, revealing that the virus does not infect all cell types simultaneously.

Oct 30, 2026·2 sources
00

Mayo Clinic study finds checkpoint immunotherapy reshapes immune environment in melanoma-affected lymph nodes

A new Mayo Clinic study reveals that checkpoint immunotherapy may reorganize the immune environment within lymph nodes after melanoma has spread to them. The research demonstrates how the treatment restructures immune cell interactions in affected lymph nodes.

Oct 30, 2026·2 sources
00

AbbVie raises annual profit forecast on strong immunology drug sales

AbbVie raised its full-year profit forecast after beating third-quarter expectations, driven by strong demand for its newer immunology and neuroscience drugs as the company navigates the Humira patent cliff.

Oct 30, 2026·2 sources
00

Ohio State researchers link gut microbiome to inflammation in spinal cord injury

Scientists at Ohio State University conducted a genome-level analysis of gut microbial communities to explore connections between spinal cord injury, inflammation, and immune function. The early study results suggest potential new therapeutic approaches to aid healing after spinal injuries.

Oct 30, 2026·3 sources
00

Fox Chase Cancer Center identifies ANO6 protein as target to slow pancreatic cancer growth

Researchers at Fox Chase Cancer Center discovered that blocking the anoctamin 6 (ANO6) protein can slow pancreatic tumor growth and reduce immune suppression in preclinical trials. The study reveals that cancer-associated fibroblasts transfer membrane lipids to cancer cells through ANO6-dependent trogocytosis, fueling tumor progression.

Oct 30, 2026·2 sources
00
Oct 29, 2026

St. Jude researchers discover COMPASS pathway that prevents autoimmune responses to gut bacteria

Scientists at St. Jude Children's Research Hospital have identified a gene-regulatory pathway called COMPASS that enables regulatory T cells to maintain immune tolerance to trillions of bacteria in the human gut. The discovery, published in Science Advances, explains how the body prevents devastating autoimmune responses to intestinal microbes.

Oct 29, 2026·2 sources
00

Study links type 1 diabetes immune changes to potential cancer protection

New research published in The Journal of Immunology reveals how high blood sugar and type 1 diabetes may protect against certain cancers including melanoma, breast and colon cancer. The findings could inform development of new cancer immunotherapy treatments by explaining the previously mysterious association between T1D and decreased cancer risk.

Oct 29, 2026·1 source
00

iDIET shows improved outcomes for eosinophilic esophagitis in randomized trial

A novel allergen-specific, immune signature-directed diet (iDIET) led to significant improvements in histologic and endoscopic responses in patients with eosinophilic esophagitis compared with a sham elimination diet, according to results from a small randomized study presented in Nashville, Tennessee.

Oct 29, 2026·1 source
00

Researchers link linoleic acid breakdown product to psoriasis itch through GPR35 receptor

Scientists have discovered that EKODE, a metabolite of commonly consumed linoleic acid fat, binds to the GPR35 receptor to trigger inflammation and itching in psoriasis. Blocking this receptor in mouse models significantly reduced both inflammation and scratching behavior.

Oct 29, 2026·2 sources
00
Oct 28, 2026

Restoring taurine amino acid can reduce age-related inflammation, Yale research finds

New research from Yale shows that restoring the amino acid taurine can diminish inflammaging—the sustained low-level inflammation that characterizes the aging process and contributes to functional decline and chronic diseases. The findings address how the innate immune system's persistent activation during aging can be modulated.

Oct 28, 2026·2 sources
00

Scientists discover neutrophil mutations trigger autoimmune response in lupus patients

Researchers at La Jolla Institute for Immunology and University of Washington found that lupus patients have unusual mutations in neutrophils that generate novel peptides, which are recognized as foreign threats by T and B cells, driving autoimmune responses and antibody production.

Oct 28, 2026·2 sources
00
Oct 23, 2026

Tegoprubart outperforms tacrolimus in preserving kidney function after transplant, BESTOW trial finds

The Phase 2 BESTOW clinical trial demonstrated that tegoprubart, a novel anti-CD40L antibody therapy, was superior to tacrolimus, the current standard of care, at preserving kidney function in adults receiving their first kidney transplant. The trial results suggest a potential advancement in immunosuppressive treatment regimens for transplant patients.

Oct 23, 2026·3 sources
00

Three drugs show sustained kidney function benefits in IgA nephropathy trials at 2 years

Atacicept, telitacicept, and sibeprenlimab demonstrated unprecedented benefits in stabilizing kidney function in phase 3 trials for IgA nephropathy, with sustained effects at two years.

Oct 23, 2026·2 sources
00

Researchers discover how chronic lymphocytic leukemia cells evade treatment by switching survival signals

A new study published in Blood Journal reveals that chronic lymphocytic leukemia (CLL) cells can switch between different survival signals to evade treatment, helping explain why therapies work for some patients but develop resistance in others. The research identifies how cancer cells alternate between low and high basal signaling states through TLR9 activation.

Oct 23, 2026·3 sources
00
Oct 22, 2026

Gilead acquires PepStar inflammation drug program for $1.28 billion

Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental IL-23 receptor inhibitor for inflammatory bowel disease, for $1.28 billion upfront in a deal that could compete with Johnson & Johnson's new immunology pill.

Oct 22, 2026·3 sources
00
Oct 21, 2026

Roivant's brepocitinib succeeds in phase 3 trials for non-infectious uveitis

Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.

Oct 21, 2026·7 sources
00
Oct 20, 2026

City of Hope identifies immune pathway behind radiation-induced lung damage

Researchers at City of Hope have discovered an immune pathway that contributes to radiation-related lung damage and identified a potential strategy to block it, according to findings published in Nature Communications. The preclinical study points to a possible approach for reducing a serious side effect of cancer radiation therapy.

Oct 20, 2026·2 sources
00
Oct 19, 2026

New research reveals shared immune dysfunction mechanisms in allergies and autoimmune diseases

Growing evidence is challenging the traditional view that allergic and autoimmune disorders are opposing forms of immune dysfunction, with researchers uncovering shared mechanisms between the two conditions that have historically been evaluated and treated separately.

Oct 19, 2026·2 sources
00
Oct 15, 2026

Osivax's flu vaccine OVX836 fails Phase 2b trial, company pivots to combination approach

French biotech Osivax announced that its lead influenza vaccine OVX836 did not meet its pre-specified primary endpoint in a Phase 2b trial, though the company reported a first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes. Osivax plans to advance a combination strategy for next-generation seasonal influenza vaccines.

Oct 15, 2026·2 sources
00
Oct 1, 2026

Pfizer's tilrekimig meets primary goal in phase 2 eczema trial

Pfizer's experimental eczema drug tilrekimig achieved significantly stronger skin clearance compared to placebo at multiple doses in a mid-stage clinical trial after 16 weeks. The company presented detailed Phase 2 results for the atopic dermatitis treatment.

Oct 1, 2026·1 source
00
Aug 10, 2026

Spatial transcriptomics reveals molecular programs linked to heart-transplant rejection

Researchers at Vanderbilt Health have published findings in Nature Cardiovascular Research showing that spatial transcriptomics of cardiac biopsies reveals significant cellular and molecular variation in transplant rejection that is not captured by conventional biopsy grading, potentially enabling precision medicine approaches to organ rejection treatment.

Aug 10, 2026·4 sources
00
Jul 30, 2026

Medical University of Vienna develops new treatment enabling kidney transplant for previously ineligible patient

An international research team led by the Medical University of Vienna has reported a breakthrough treatment strategy that successfully enabled a kidney transplant for a patient who had no realistic chance of receiving a suitable donor organ through conventional methods.

Jul 30, 2026·1 source
00

Top claims

  • ▪When LATS1 and LATS2 regulators are lost, restraint on YAP and TAZ weakens, leading to increased YAP and TAZ activity in tumor cells.
  • ▪A Hiroshima University study published in Communications Biology found that hyperactive YAP and TAZ proteins drive up PD-L2 expression while increasing genomic instability in cancer cells.
  • ▪Loss of LATS1 and LATS2 regulators in laboratory models was accompanied by increased YAP and TAZ activity, greater genomic instability, and elevated DNA damage in tumor cells.

Subtopics

Biomedical research12Clinical trials6Autoimmune disease5Cancer & Oncology5Cancer research5Drug development5Autoimmune disease treatments4Cancer immunotherapy4Molecular biology4Cancer treatment3Digestive diseases3Organ transplantation3Pharmaceutical Industry3Randomized controlled trial3Biotech innovation2Cancer2Cancer and Cancer Treatment2Drug Policy, Pricing & Approval2Genomics2Gut microbiome2Inflammation reduction & immune effects2Neuroscience2Nutrition2Oncology2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories